128 related articles for article (PubMed ID: 18303433)
1. The effect of FDG-PET on the stage distribution of non-small cell lung cancer.
Morgensztern D; Goodgame B; Baggstrom MQ; Gao F; Govindan R
J Thorac Oncol; 2008 Feb; 3(2):135-9. PubMed ID: 18303433
[TBL] [Abstract][Full Text] [Related]
2. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Scheiderbauer J; Budach W; Kotzerke J; Bares R
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
[TBL] [Abstract][Full Text] [Related]
3. [Staging with 18F-FDG-PET/CT influences stage-specific survival in advanced non-small cell lung cancer (NSCLC)].
Tönnies S; Bauer TT; Misch D; Boch C; Blum T; Bittner RC; Förster GJ; Kollmeier J
Pneumologie; 2012 Apr; 66(4):212-7. PubMed ID: 22477481
[TBL] [Abstract][Full Text] [Related]
4. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
Kim MP; Correa AM; Hofstetter W; Mehran R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Erasmus JJ; Swisher SG
Ann Thorac Surg; 2015 Feb; 99(2):414-20. PubMed ID: 25497068
[TBL] [Abstract][Full Text] [Related]
5. Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.
Gauger J; Patz EF; Coleman RE; Herndon JE
J Thorac Oncol; 2007 Jun; 2(6):499-505. PubMed ID: 17545844
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
[TBL] [Abstract][Full Text] [Related]
7. Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.
Raghunathan R; Cease K; Troeschel S; Zhao L; Gross M; Chen G; Chopra V; Ramnath N
Am J Clin Oncol; 2018 May; 41(5):513-518. PubMed ID: 27322696
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
[TBL] [Abstract][Full Text] [Related]
9. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
[TBL] [Abstract][Full Text] [Related]
10. [Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
Liu SW; Yu JM; Xing LG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):626-9. PubMed ID: 15634527
[TBL] [Abstract][Full Text] [Related]
11. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
Farrell MA; McAdams HP; Herndon JE; Patz EF
Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
[TBL] [Abstract][Full Text] [Related]
12. Prognostic stratification using F-18 FDG PET/CT in patients with advanced stage (stage III and IV) non-small cell lung cancer.
Kim YS; Lee MK; Kim SJ; Kim IJ; Kim YK; Jo WS; Park SK
Neoplasma; 2010; 57(3):241-6. PubMed ID: 20353275
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
14. Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003.
Dinan MA; Curtis LH; Carpenter WR; Biddle AK; Abernethy AP; Patz EF; Schulman KA; Weinberger M
J Clin Oncol; 2012 Aug; 30(22):2725-30. PubMed ID: 22753917
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic values of FDG-PET in patients with non-small cell lung cancer.
Abe K; Baba S; Kaneko K; Isoda T; Yabuuchi H; Sasaki M; Sakai S; Yoshino I; Honda H
Clin Imaging; 2009; 33(2):90-5. PubMed ID: 19237050
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
Hoopes DJ; Tann M; Fletcher JW; Forquer JA; Lin PF; Lo SS; Timmerman RD; McGarry RC
Lung Cancer; 2007 May; 56(2):229-34. PubMed ID: 17353064
[TBL] [Abstract][Full Text] [Related]
17. Improved non-invasive T-Staging in non-small cell lung cancer by integrated 18F-FDG PET/CT.
Pauls S; Buck AK; Hohl K; Halter G; Hetzel M; Blumstein NM; Mottaghy FM; Glatting G; Krüger S; Sunder-Plassmann L; Möller P; Hombach V; Brambs HJ; Reske SN
Nuklearmedizin; 2007; 46(1):9-14; quiz N1-2. PubMed ID: 17299649
[TBL] [Abstract][Full Text] [Related]
18. Impact of FDG-PET-induced treatment choices on long-term outcome in non-small cell lung cancer.
Wauters I; Stroobants S; De Leyn P; D'Hoore I; Nackaerts K; Dooms C; Vansteenkiste J
Respiration; 2010; 79(2):97-104. PubMed ID: 19420903
[TBL] [Abstract][Full Text] [Related]
19. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
[TBL] [Abstract][Full Text] [Related]
20. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
